JP2020535796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535796A5 JP2020535796A5 JP2020513309A JP2020513309A JP2020535796A5 JP 2020535796 A5 JP2020535796 A5 JP 2020535796A5 JP 2020513309 A JP2020513309 A JP 2020513309A JP 2020513309 A JP2020513309 A JP 2020513309A JP 2020535796 A5 JP2020535796 A5 JP 2020535796A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- fusion protein
- seq
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims description 100
- 108091033319 polynucleotide Proteins 0.000 claims description 100
- 239000002157 polynucleotide Substances 0.000 claims description 100
- 239000000427 antigen Substances 0.000 claims description 94
- 102000036639 antigens Human genes 0.000 claims description 94
- 108091007433 antigens Proteins 0.000 claims description 94
- 102000037865 fusion proteins Human genes 0.000 claims description 90
- 108020001507 fusion proteins Proteins 0.000 claims description 90
- 150000001413 amino acids Chemical group 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 51
- 210000002865 immune cell Anatomy 0.000 claims description 44
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 claims description 34
- 239000003550 marker Substances 0.000 claims description 31
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 29
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 24
- 230000003834 intracellular effect Effects 0.000 claims description 20
- 108091008874 T cell receptors Proteins 0.000 claims description 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 239000002458 cell surface marker Substances 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 12
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 10
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 10
- 239000012636 effector Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 102000018697 Membrane Proteins Human genes 0.000 claims description 9
- 108010052285 Membrane Proteins Proteins 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 108010003639 CD56 Antigen Proteins 0.000 claims description 4
- 102000004652 CD56 Antigen Human genes 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 230000003463 hyperproliferative effect Effects 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108010056308 A-1 antigen Proteins 0.000 claims description 2
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 claims description 2
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 2
- 108010071965 CD24 Antigen Proteins 0.000 claims description 2
- 102000007645 CD24 Antigen Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 101150091887 Ctla4 gene Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 2
- 108010091373 HA-1 antigen Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 108010073816 IgE Receptors Proteins 0.000 claims description 2
- 102000009438 IgE Receptors Human genes 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 108010052781 Interleukin-3 Receptor alpha Subunit Proteins 0.000 claims description 2
- 102000018883 Interleukin-3 Receptor alpha Subunit Human genes 0.000 claims description 2
- 108010044023 Ki-1 Antigen Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 claims description 2
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 claims description 2
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 2
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 2
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims description 2
- 102100036407 Thioredoxin Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 2
- CFDVGUXRLQWLJX-QGTNPELVSA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO CFDVGUXRLQWLJX-QGTNPELVSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 238000003209 gene knockout Methods 0.000 claims description 2
- 102000046689 human FOLH1 Human genes 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 229920002643 polyglutamic acid Polymers 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 108060008226 thioredoxin Proteins 0.000 claims description 2
- 229940094937 thioredoxin Drugs 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 238000002679 ablation Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003704A JP2023029624A (ja) | 2017-09-06 | 2023-01-13 | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555012P | 2017-09-06 | 2017-09-06 | |
| US62/555,012 | 2017-09-06 | ||
| PCT/US2018/049804 WO2019051128A1 (en) | 2017-09-06 | 2018-09-06 | SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003704A Division JP2023029624A (ja) | 2017-09-06 | 2023-01-13 | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535796A JP2020535796A (ja) | 2020-12-10 |
| JP2020535796A5 true JP2020535796A5 (enExample) | 2021-10-14 |
| JP7407701B2 JP7407701B2 (ja) | 2024-01-04 |
Family
ID=63788013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513309A Active JP7407701B2 (ja) | 2017-09-06 | 2018-09-06 | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 |
| JP2023003704A Pending JP2023029624A (ja) | 2017-09-06 | 2023-01-13 | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003704A Pending JP2023029624A (ja) | 2017-09-06 | 2023-01-13 | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210023132A1 (enExample) |
| EP (1) | EP3679072A1 (enExample) |
| JP (2) | JP7407701B2 (enExample) |
| CN (1) | CN111051349A (enExample) |
| AU (1) | AU2018327225A1 (enExample) |
| CA (1) | CA3071661A1 (enExample) |
| WO (1) | WO2019051128A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201906T1 (hr) | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
| CN112250767B (zh) * | 2020-12-08 | 2021-05-18 | 北京艺妙神州医药科技有限公司 | 一种结合Strep-Tag II标签的抗体及其应用 |
| CN115368470A (zh) * | 2021-05-21 | 2022-11-22 | 南京卡提医学科技有限公司 | 靶向b7-h3的嵌合受体及其用途 |
| WO2023081727A1 (en) * | 2021-11-02 | 2023-05-11 | Fred Hutchinson Cancer Center | Treatments for cancers utilizing cell-targeted therapies and associated research protocols |
| WO2024152962A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗tt3的人源化抗体及其应用 |
| WO2024240064A1 (zh) * | 2023-05-19 | 2024-11-28 | 贝达药业股份有限公司 | 靶向抗原表位多肽的抗体药物偶联物及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| WO2003078619A1 (en) | 2002-03-15 | 2003-09-25 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| EP1590468A2 (en) | 2003-01-28 | 2005-11-02 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| ES2626025T3 (es) | 2005-10-18 | 2017-07-21 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| AU2007263265A1 (en) * | 2006-06-21 | 2007-12-27 | Apogenix Gmbh | Differential IL-4 and/or IL-10 cytokine expression in human cancer |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| EP2318441A2 (en) * | 2008-07-14 | 2011-05-11 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| FI3597749T3 (fi) | 2012-05-25 | 2023-10-09 | Univ California | Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten |
| KR101342974B1 (ko) * | 2012-11-06 | 2013-12-18 | 명지대학교 산학협력단 | 신규 펩티드 태그 및 이의 용도 |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| EP2932421A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| EP2871189A1 (en) | 2013-11-07 | 2015-05-13 | Institut Pasteur | High-affinity monoclonal anti-strep-tag antibody |
| US20160298096A1 (en) | 2013-11-18 | 2016-10-13 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| HRP20201906T1 (hr) * | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| CN113698485A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| CA2976926A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
| JP6985934B2 (ja) * | 2015-04-29 | 2021-12-22 | フレッド ハッチンソン キャンサー リサーチ センター | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| US11517627B2 (en) * | 2017-01-20 | 2022-12-06 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| US20200262894A1 (en) * | 2017-09-06 | 2020-08-20 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
-
2018
- 2018-09-06 WO PCT/US2018/049804 patent/WO2019051128A1/en not_active Ceased
- 2018-09-06 JP JP2020513309A patent/JP7407701B2/ja active Active
- 2018-09-06 CA CA3071661A patent/CA3071661A1/en active Pending
- 2018-09-06 EP EP18782835.5A patent/EP3679072A1/en active Pending
- 2018-09-06 AU AU2018327225A patent/AU2018327225A1/en active Pending
- 2018-09-06 CN CN201880057804.1A patent/CN111051349A/zh active Pending
- 2018-09-06 US US16/644,947 patent/US20210023132A1/en not_active Abandoned
-
2023
- 2023-01-13 JP JP2023003704A patent/JP2023029624A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535796A5 (enExample) | ||
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| JP6840682B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP7082574B2 (ja) | 免疫療法用改変細胞 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| JP2023078394A (ja) | Ｃａｒ－ｔ細胞の調節方法 | |
| KR20200015713A (ko) | 항-trbc1 항원 결합 도메인 | |
| CA3075619A1 (en) | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking | |
| CN112794916B (zh) | 三特异性抗原结合构建体及构建方法和应用 | |
| CA3030837A1 (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| CN110088133A (zh) | 抗独特型抗体及相关方法 | |
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| KR20220035367A (ko) | 항-dll3 키메라 항원 수용체 및 이의 용도 | |
| JP2015527070A5 (enExample) | ||
| CA3223034A1 (en) | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases | |
| JP2023087005A (ja) | Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用 | |
| JP2020530859A (ja) | 免疫調節剤としてのｃｄ９６結合剤 | |
| CN114206919B (zh) | 靶向taci的抗体和嵌合抗原受体 | |
| CA3079363A1 (en) | Multispecific antigen binding proteins | |
| JP2023542900A (ja) | ４－１ｂｂを標的とする単一ドメイン抗体、その融合タンパク質、その医薬組成物及び使用 | |
| CA3234046A1 (en) | Anti-bcma single domain antibodies and therapeutic constructs | |
| WO2023246911A1 (zh) | 基于t细胞受体的双特异性多肽分子及其用途 | |
| WO2025251924A1 (zh) | 特异性结合cd3/tcr复合物的纳米抗体或其抗原结合片段及其应用 | |
| WO2025087436A1 (zh) | 基于t细胞受体的多特异性多肽分子及其组合物和用途 | |
| HK40077185A (en) | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |